Allspring Global Investments Holdings LLC Has $3.80 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Allspring Global Investments Holdings LLC trimmed its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 23.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 187,414 shares of the company’s stock after selling 58,558 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Tarsus Pharmaceuticals were worth $3,795,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TARS. RTW Investments LP lifted its holdings in shares of Tarsus Pharmaceuticals by 13.1% during the 3rd quarter. RTW Investments LP now owns 2,880,701 shares of the company’s stock worth $51,190,000 after acquiring an additional 332,576 shares during the period. BlackRock Inc. boosted its holdings in Tarsus Pharmaceuticals by 51.0% during the second quarter. BlackRock Inc. now owns 2,199,753 shares of the company’s stock valued at $39,750,000 after purchasing an additional 742,493 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Tarsus Pharmaceuticals by 25.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,551,802 shares of the company’s stock valued at $27,576,000 after purchasing an additional 316,128 shares during the period. Deerfield Management Company L.P. Series C acquired a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter worth approximately $13,399,000. Finally, Geode Capital Management LLC lifted its position in shares of Tarsus Pharmaceuticals by 27.4% during the 2nd quarter. Geode Capital Management LLC now owns 444,861 shares of the company’s stock worth $8,039,000 after buying an additional 95,712 shares during the period. 90.01% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on TARS. Oppenheimer reiterated an “outperform” rating and set a $59.00 price objective (up from $55.00) on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 28th. Barclays lifted their price target on shares of Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, February 28th. HC Wainwright upped their price objective on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Lifesci Capital reaffirmed an “outperform” rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, December 26th. Finally, Jefferies Financial Group boosted their target price on Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $48.38.

Tarsus Pharmaceuticals Price Performance

TARS opened at $32.44 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.93 and a quick ratio of 6.85. The company’s 50 day simple moving average is $33.83 and its 200-day simple moving average is $24.33. Tarsus Pharmaceuticals, Inc. has a one year low of $12.57 and a one year high of $40.40.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($1.31) EPS for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.06. The firm had revenue of $13.08 million during the quarter, compared to the consensus estimate of $4.63 million. During the same quarter in the previous year, the business posted ($0.49) earnings per share. Sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -4.25 EPS for the current fiscal year.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 4,436 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $135,741.60. Following the transaction, the general counsel now directly owns 40,951 shares in the company, valued at approximately $1,253,100.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Bobak R. Azamian sold 10,415 shares of Tarsus Pharmaceuticals stock in a transaction on Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $318,699.00. Following the completion of the sale, the chief executive officer now directly owns 26,456 shares of the company’s stock, valued at $809,553.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Bryan Wahl sold 4,436 shares of the stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $135,741.60. Following the completion of the transaction, the general counsel now directly owns 40,951 shares in the company, valued at approximately $1,253,100.60. The disclosure for this sale can be found here. Insiders sold a total of 24,496 shares of company stock worth $749,578 over the last three months. 11.54% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.